Abstracts tagged "Lupus"

Abstract Number: 2008 • 2016 ACR/ARHP Annual Meeting
Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE
Zhi-Wei Lai¹, Ivan Marchena², Hajra Tily², Ricardo Garcia¹, Julie Yu², Lisa Francis², Maha Dawood², Ryan Kelly², Stephen Faraone², Paul E. Phillips³ and Andras Perl⁴, ¹Medicine, SUNY, Syracuse, NY, ²SUNY, Syracuse, NY, ³Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, ⁴Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: The rationale for this prospective, biomarker-driven, open-label clinical trial of rapamycin (ClinicalTrials.gov Identifier: NCT00779194) has been based on growing evidence for involvement of the…
Abstract Number: 2886 • 2016 ACR/ARHP Annual Meeting
Associations Between Type I Interferon and Antiphospholipid Antibody Status Differ Between Ancestral Backgrounds
Taro Iwamoto¹, Meenakshi Jolly² and Timothy B. Niewold³, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Rush, Chicago, IL, ³Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Autoantibodies in SLE that bind to double-stranded DNA or RNA-binding proteins are strongly associated with high levels of type I interferon (IFN), likely via…
Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…
Abstract Number: 1393 • 2016 ACR/ARHP Annual Meeting
Mycophenolic Acid Pharmacokinetics in Childhood-Onset Systemic Lupus Erythematosus Patients of Hispanic Ethnicity in a Single Center
Anna Carmela Sagcal-Gironella¹, Marietta De Guzman¹, Daping Zhang², Lorita Agu² and Diana Chow², ¹Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX
Background/Purpose: Mycophenolic acid (MPA) is the biologically active metabolite of mycophenolate mofetil (MMF), a widely used immunosuppressant in the treatment of childhood-onset systemic lupus erythematosus…
Abstract Number: 2024 • 2016 ACR/ARHP Annual Meeting
Effect of a Revised Counselor Training on Skills Development and Knowledge of Volunteers with Systemic Lupus Erythematosus
Melissa T. Flores¹, Jillian A. Rose², Priscilla Toral¹, Roberta Horton¹ and Janice Karbachinskiy³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³New York-Presbyterian Hospital Weill Cornell, New York, NY
Background/Purpose: A needs assessment was conducted on an evidenced-based, national lupus telephone peer counseling service, ongoing since 1988, with 30,000+ client contacts to date. We…
Abstract Number: 2932 • 2016 ACR/ARHP Annual Meeting
HLA-DR3 Restricted Response to Lupus-Related Auto-Antigen Smd: Autoreactive T Cells Are Inherent in Normal Immune Repertoires
Zhenhuan Zhao¹, Jiling Ren¹, Chao Dai², Carol Kannapell¹, Qian Wang³, Felicia Gaskin⁴ and Shu Man Fu⁵, ¹Medicine/CIIR/Rheumatology, University of Virginia, Charlottesville, VA, ²Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA, ⁴Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, ⁵Department of Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: HLA class II is the major susceptibility region for systemic lupus erythematosus (SLE) and other autoimmune disorders such as rheumatoid arthritis, multiple sclerosis and…
Abstract Number: 1053 • 2016 ACR/ARHP Annual Meeting
Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Melissa T. Flores¹, Jillian A. Rose², Priscilla Toral¹, Roberta Horton¹, Dariana M. Pichardo¹, Lillian Mendez¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Research shows that chronic illnesses such as SLE have multi-level impact on the family; it can be challenging for both patients & caregivers to…
Abstract Number: 1395 • 2016 ACR/ARHP Annual Meeting
Regional Brain Gray Matter Volume Loss in Children and Adolescents with SLE
Andrea Knight¹, Michelle Vickery², Jimit Doshi³, Guray Erus⁴, Arastoo Vossough⁵ and Susan Furth⁶, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Section of Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁴Section on Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁵Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neuropsychiatric SLE in children and adolescents presents diagnostic challenge due to limitations of conventional magnetic resonance imaging (MRI) to detect clinically relevant brain changes.…
Abstract Number: 2025 • 2016 ACR/ARHP Annual Meeting
Lupus Education Advancement Project (LEAP): Rheumatology Fellows Serving As Educators Increased Knowledge and Efficiency in Lupus Recognition and Referral By Providers in Primary and Emergency Care
Diane Gross¹, Amy Caron², Irene Blanco³, Alfred Denio⁴, Sheetal Desai⁵, Amanda Sammut⁶ and Zoon Naqvi⁷, ¹S.L.E. Lupus Foundation/Lupus Research Institute, New York, NY, ²Lupus Research Institute, Ny, NY, ³Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, ⁴Rheumatology, Geisinger Medical Center, Danville, PA, ⁵Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA, ⁶NYC Health and Hospitals/Harlem Hospital Center and Columbia University Medical Center, New York, NY, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Primary and emergency care providers may have received 45 minutes of lupus education in medical school. Providers may fail in recognizing lupus because symptoms…
Abstract Number: 3102 • 2016 ACR/ARHP Annual Meeting
Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Aditya Joshi³, Joseph Lerman⁴, Michael Davis³, Alice Fike⁵, Amit Dey⁶, Taufiq Salahuddin⁷, Balaji Natarajan³, Martin P. Playford⁷, Heather Teague³, Zerai G. Manna⁵, Marcus Chen³, Sarfaraz Hasni⁵, Nehal N. Mehta⁷ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Clinical Center, NIH, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, when compared…
Abstract Number: 1067 • 2016 ACR/ARHP Annual Meeting
History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Thrombocytopenia is a common feature of both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and in the former most frequently results from antiplatelet…
Abstract Number: 1744 • 2016 ACR/ARHP Annual Meeting
Expression of C1q By Podocytes at Late Stages of Proliferative Lupus Glomerulonephritis
Hongyang Wang¹, Ou Jin², Niansheng Yang³, Chao Dai¹, Sun-sang Sung¹, Felicia Gaskin⁴ and Shu Man Fu⁵, ¹Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, ²Rheumatology, Sun Yat-sen University Third Affiliated Hospital, Guangzhou, China, ³Rheumatology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China, ⁴Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, ⁵Department of Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: In NZM2328 (NZM), a mouse model of proliferative lupus glomerulonephritis (GN), lupus GN can be categorized to four stages, i.e. normal, acute GN (aGN),…
Abstract Number: 2058 • 2016 ACR/ARHP Annual Meeting
Ectonucleotidase-Mediated Protection of Lupus Mice from Exaggerated Immune Responses and Arterial Vasculopathy
Jason S Knight¹, Levi F Mazza¹, Srilakshmi Yalavarthi¹, Yogen Kanthi² and David J Pinsky², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: CD39 and CD73 are so-called ectonucleotidases, surface enzymes expressed by leukocytes and endothelial cells that jut into the extracellular space. There, they mediate the…
Abstract Number: 3106 • 2016 ACR/ARHP Annual Meeting
A Simple Test for Assessing and Monitoring SLE Disease Activity Status
Chaim Putterman¹, Michael Rowe², Joseph Barten Legutki², Theodore M. Tarasow² and Kathryn Sykes², ¹Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ²HealthTell, Inc, san ramon, CA
Background/Purpose: SLE patients can experience chronically active disease, remissions and flares, or long periods of quiescence. Accurately assessing disease activity is crucial for prescribing appropriate…
Abstract Number: 1070 • 2016 ACR/ARHP Annual Meeting
Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients
Mariana Moreno Ramirez¹, Luis M. Amezcua-Guerra², Victor Alejandro Escamilla Gomez³, Daniel Hernandez³, Luis Fernando Perez¹, Javier Loaiza Felix¹ and Angelica Vargas Guerrero¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Rheumatology, InstitutoNacional de Cardiología Ignacio Chavez, Mexico City, Mexico
Background/Purpose: In APS, irreversible organ damage may result of disease activity, medications, or comorbid illnesses. To assess it, different methods have been used including the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].